Menu

New Ovarian Cancer Vaccine Shows Promise

A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.

Apr 12, 2018
Catherine Offord

A human T cellWIKIMEDIA, NIAID, NIHOvarian cancer is a particularly hard-to-treat disease. It’s often diagnosed late, and even after surgery and chemotherapy, around 85 percent of patients relapse and develop chemoresistance. But a preliminary clinical trial, carried out by researchers at the University of Pennsylvania, has shown promising results for a new type of vaccine that aims to boost patients’ immune systems to fight the disease. The findings were published yesterday (April 11) in Science Translational Medicine.

“This vaccine appears to be safe for patients, and elicits a broad anti-tumor immunity,” study coauthor Janos Tanyi of the University of Pennsylvania’s Perelman School of Medicine says in a statement. “We think it warrants further testing in larger clinical trials.”

The researchers focused on patients with recurrent advanced epithelial ovarian cancer, which has a five-year survival rate of around 17 percent. First, the team extracted dendritic cells—antigen-presenting cells that help prime T-cell responses—from each patient, and grew them in the presence of antigens from that same patient’s tumor. Then, they injected the dendritic cells back into the patient’s lymph nodes to trigger an antitumor T-cell response.

In the trial, all 25 patients received a series of such injections, either alone or in combination with chemotherapy drugs. None of the vaccinated patients reported severe side-effects, and patients who received the vaccine along with two chemotherapy drugs had a two-year survival rate of 78 percent—compared with just 44 percent for patients in a control cohort receiving only chemotherapy. Tanyi tells the Los Angeles Times that the vaccine appears to be “so safe it’s unbelievable.”

Otis Brawley, chief medical officer of the American Cancer Society tells CNN that the study “clearly justifies a larger clinical trial.” But he also cautioned against overstating the promise of the team’s personalized approach compared to tried-and-tested treatments. The public “often wants to pass up better-proven conventional therapy for an unknown in immunotherapy,” he says.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.